Table 2 Blood pressure lowering medication at baseline and end of follow-up
| Â | Background metformin | Background sulfonylurea | ||
|---|---|---|---|---|
| Â | + rosiglitazone | + sulfonylurea | + rosiglitazone | + metformin |
Modified ITT population (n) | 176 | 165 | 160 | 167 |
Type of medication (n (%)) | Â | Â | Â | Â |
   Baseline |  |  |  |  |
    Any BP medication | 119 (68) | 112 (68) | 104 (65) | 114 (68) |
    ACEi/ARB | 91 (52) | 83 (50) | 80 (50) | 88 (53) |
    β-blocker | 44 (25) | 42 (25) | 34 (21) | 43 (26) |
    CCB | 37 (21) | 33 (20) | 28 (17) | 36 (22) |
    Diuretics | 28 (16) | 34 (21) | 26 (16) | 38 (23) |
   End of follow-up* |  |  |  |  |
    Any BP medication | 131 (74) | 124 (75) | 119 (74) | 121 (72) |
    ACEi/ARB | 99 (56) | 93 (56) | 89 (56) | 92 (55) |
    β-blocker | 51 (29) | 53 (32) | 40 (25) | 46 (27) |
    CCB | 47 (27) | 39 (24) | 32 (20) | 40 (24) |
    Diuretics | 48 (27) | 39 (24) | 34 (21) | 41 (25) |
Number of drug classes (n (%)) | Â | Â | Â | Â |
   Baseline |  |  |  |  |
    0 | 57 (32) | 53 (32) | 56 (35) | 53 (32) |
    1 | 62 (35) | 47 (28) | 51 (32) | 47 (28) |
    2 | 34 (19) | 45 (27) | 37 (23) | 43 (26) |
    3 | 17 (10) | 15 (9) | 14 (9) | 20 (12) |
    > 3 | 6 (3) | 5 (3) | 2 (1) | 4 (2) |
   End of follow-up |  |  |  |  |
    0 | 45 (25) | 41 (25) | 41 (26) | 46 (27) |
    1 | 57 (32) | 47 (28) | 58 (36) | 45 (27) |
    2 | 34 (19) | 47 (28) | 41 (26) | 50 (30) |
    3 | 27 (15) | 22 (13) | 15 (9) | 19 (11) |
    > 3 | 13 (7) | 8 (5) | 5 (3) | 7 (4) |